Document is current

Any future updates will be listed below

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA

Crossref DOI link: https://doi.org/10.1007/s12185-021-03205-8

Published Online: 2021-08-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark